Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Saori Takamura, Yuichi Teraki, Eri Katayama, Takumi Kawaguchi, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Sumiko Nagoshi, Takekuni Nakama, Takuji Torimura

Clin Mol Hepatol. 2022;28(2):269-272. Published online February 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0040

View: 3452 Download: 286 Citations: 5

Reply: Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis

Jihyun An, Ju Hyun Shim

Clin Mol Hepatol. 2022;28(2):267-268. Published online January 18, 2022

DOI: https://doi.org/10.3350/cmh.2022.0013

View: 2225 Download: 46

Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis

Yi-Chun Huang, Chih-Wei Chen, James Chun-Chung Wei

Clin Mol Hepatol. 2022;28(2):265-266. Published online January 4, 2022

DOI: https://doi.org/10.3350/cmh.2021.0412

View: 5717 Download: 37 Citation: 1

Impact of branched-chain amino acids and frailty on the management of lenvatinib-related fatigue in patients with hepatocellular carcinoma

Shigeo Shimose, Shunji Koya, Takumi Kawaguchi, Keisuke Hirota, Sachiyo Yoshio, Takashi Niizeki, Hiroo Matsuse, Takuji Torimura

Clin Mol Hepatol. 2021;27(4):616-619. Published online September 13, 2021

DOI: https://doi.org/10.3350/cmh.2021.0258

View: 3673 Download: 187 Citations: 3

The major diagnostic role of autoantibodies in the diagnosis of autoimmune hepatitis, a disease of all ages

Linda Beenet

Clin Mol Hepatol. 2021;27(3):510-511. Published online March 22, 2021

DOI: https://doi.org/10.3350/cmh.2021.0058

View: 3060 Download: 143 Citation: 1

Clinical and serological prognostic markers in primary biliary cholangitis

Markus Wilhelmi

Clin Mol Hepatol. 2021;27(2):360-361. Published online March 23, 2021

DOI: https://doi.org/10.3350/cmh.2021.0088

View: 2794 Download: 98

A dilemma that probably would never resolve

Ravi Thanage, Shubham Jain, Sanjay Chandnani, Pravin Rathi

Clin Mol Hepatol. 2021;27(1):219-220. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0274

View: 2717 Download: 68

Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?

Dimitrios Patoulias, Michael Doumas

Clin Mol Hepatol. 2020;26(4):582-583. Published online September 25, 2020

DOI: https://doi.org/10.3350/cmh.2020.0264

View: 2917 Download: 63 Citations: 2

Phosphoinositide 3-kinase inhibitors are effective therapeutic drugs for the treatment of hepatocellular carcinoma?

Jeong Su Park, Soo Han Bae

Clin Mol Hepatol. 2020;26(4):577-578. Published online September 17, 2020

DOI: https://doi.org/10.3350/cmh.2020.0143

View: 2976 Download: 62 Citation: 1

Macro-aspartate aminotransferase in a healthy woman

Maria Lorubbio, Agostino Ognibene, Benedetta Salvadori, Alessandra Fanelli, Giacomo Laffi

Clin Mol Hepatol. 2020;26(3):378-381. Published online June 23, 2020

DOI: https://doi.org/10.3350/cmh.2020.0069

View: 4027 Download: 125 Citations: 2

Viewed By 4998	A decade of liver organoids: Advances in disease modeling
Viewed By 4746	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3912	Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy
Viewed By 3029	MAFLD: How is it different from NAFLD?
Viewed By 2468	Management of refractory ascites

Cited By 117	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Cited By 54	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 52	From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Cited By 46	Obesity and the risk of primary liver cancer: A systematic review and meta-analysis
Cited By 46	Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis

Letter to the Editor